Back to top
more

Heska Corporation (HSKA)

(Delayed Data from NSDQ)

$79.28 USD

79.28
71,295

+3.36 (4.43%)

Updated May 3, 2019 04:00 PM ET

After-Market: $79.10 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Seattle Genetics (SGEN): FDA Lifts Hold on Trial of AML Drug

by Zacks Equity Research

Seattle Genetics, Inc. (SGEN) announced that the FDA has lifted the clinical hold on two phase I trials of its candidate, vadastuximab talirine (SGN-CD33A; 33A).

    GlaxoSmithKline's Nucala Positive in Label Expansion Study

    by Zacks Equity Research

    GlaxoSmithKline plc. (GSK) announced that a phase IIIb study evaluating its respiratory drug Nucala (mepolizumab) met all its primary and secondary endpoints.

      Adaptimmune Therapeutics (ADAP) Jumps: Stock Rises 10.5%

      by Zacks Equity Research

      Adaptimmune Therapeutics plc (ADAP) shares rose over 10% in the last trading session.

        Nabriva Therapeutics (NBRV) Catches Eye: Stock Gains 9.8%

        by Zacks Equity Research

        Nabriva Therapeutics AG (NBRV) moved big last session, as its shares rose almost 10% on the day.

          Tirthankar Chakraborty headshot

          New Strong Buy Stocks for March 3rd

          by Tirthankar Chakraborty

          Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

            Incyte Treats First Patient in Phase II GVHD Study on Jakafi

            by Zacks Equity Research

            Incyte Corporation (INCY) announced that the first patient has been treated in the pivotal phase II REACH-1 study assessing its marketed drug Jakafi, in combination with corticosteroids, for the treatment of GVHD.

              Abbott Labs to Close St. Jude Acquisition Later this Week

              by Zacks Equity Research

              Abbott Laboratories (ABT) announced to close the acquisition of St. Jude Medical, Inc., (STJ) on Jan 4, 2017.

                Immunomedics Completes Enrollment In Cancer Drug Study

                by Zacks Equity Research

                Immunomedics (IMMU) achieved the planned enrollment in a phase II study on IMMU-132.

                  Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate

                  by Zacks Equity Research

                  Cempra (CEMP) announced that it received a CRL from the FDA relating to its new drug applications for oral and intravenous formulation of candidate solithromycin.

                    Corbus Concludes Phase II study of Cystic Fibrosis Candidate

                    by Zacks Equity Research

                    Corbus Pharmaceuticals Holdings, Inc. (CRBP), recently announced that it has concluded Phase II trial evaluating pipeline candidate, JBT-101 (resunab), for the treatment of cystic fibrosis (CF).

                      Abbott to Sell 2 Medical Device Businesses for St. Jude Buyout

                      by Zacks Equity Research

                      Abbott Laboratories (ABT) has agreed to divest two medical device businesses in order to settle Federal Trade Commission (FTC) charges in relation to its proposed acquisition of St. Jude Medical (STJ).

                        McKesson (MCK) Closes Rexall Health Acquisition in Canada

                        by Zacks Equity Research

                        McKesson Corporation (MCK) announced that it has completed the acquisition of Canada-based Rexall Health for $2.1 billion

                          ImmunoGen: Phase I Data on Ovarian Cancer Drug Published

                          by Zacks Equity Research

                          ImmunoGen, Inc. (IMGN) announced that data from a 46-patient phase I expansion cohort study on its lead pipeline candidate, mirvetuximab soravtansine (IMGN853), were published in the Journal of Clinical Oncology.

                            Achillion Receives $15M from J&J for HCV Study Enrolment

                            by Zacks Equity Research

                            Achillion Pharmaceuticals, Inc. (ACHN) announced that it has received a milestone payment of $15 million from Johnson & Johnson's (JNJ) pharma wing, Janssen for the initiation of patient enrollment in the OMEGA-1 phase IIb global study of JNJ-4178.

                              Amphastar Stock Down on CRL for Asthma Drug in the U.S.

                              by Zacks Equity Research

                              Amphastar Pharmaceuticals, Inc. (AMPH) announced that its subsidiary, Armstrong Pharmaceuticals, Inc., has received a Complete Response Letter (CRL) from the FDA for Primatene Mist (epinephrine inhalation aerosol).

                                Shire Gets FDA Approval for Label Expansion of Adynovate

                                by Zacks Equity Research

                                Shire announced that the FDA has approved the use of hemophilia A drug, Adynovate,in pediatric patients under 12 years of age

                                  Apricus Launches Vitaros in Lebanon for Erectile Dysfunction

                                  by Zacks Equity Research

                                  Apricus Biosciences, Inc. (APRI) announced that its topical cream, Vitaros for the treatment of erectile dysfunction (ED) has been launched in Lebanon by partner Elis Pharmaceuticals Ltd.

                                    Neothetics (NEOT) Begins Phase II Study on Lead Candidate

                                    by Zacks Equity Research

                                    Neothetics, Inc. (NEOT) announced that it has commenced a phase II proof-of-concept study, LIPO-202-CL-31, on its lead candidate, LIPO-202, for the reduction of submental subcutaneous fat.

                                      Seattle Genetics' Acute Myeloid Leukemia Drug on FDA Hold

                                      by Zacks Equity Research

                                      Seattle (SGEN) announced that the FDA had placed a clinical hold or partial clinical hold on several early-stage studies on SGN-CD33A for the treatment of AML.

                                        Horizon's Rare Disease Drug Quinsair Launched in Canada

                                        by Zacks Equity Research

                                        Horizon Pharma plc (HZNP) announced the availability of Quinsair (levofloxacin inhalation solution) in Canada for the management of chronic pulmonary infections.

                                          Synergy Reports Positive Top-Line Phase III Data on IBS Drug

                                          by Zacks Equity Research

                                          Synergy Pharmaceuticals announced positive top-line data from a pivotal phase III study evaluating the efficacy and safety of its investigational drug, plecanatide, for the treatment of adult patients suffering from irritable bowel syndrome.

                                            Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy

                                            by Zacks Equity Research

                                            Ionis (IONS) and Biogen (BIIB) announced that FDA has approved Spinraza under Priority Review for the treatment of spinal muscular atrophy.

                                              Aerie (AERI) Rhopressa Regulatory Application Delayed Again

                                              by Zacks Equity Research

                                              Aerie (AERI)'s NDA for lead candidate, Rhopressa, gets delayed again due to delay on the manufacturer's part.

                                                Ionis Receives $5 Million Milestone from J&J Unit for GI Drug

                                                by Zacks Equity Research

                                                Ionis Pharmaceuticals, Inc. (IONS) announced that it has earned $5 million milestone payment from Janssen Biotech, Inc., a pharmaceutical division of Johnson & Johnson (JNJ).

                                                  Celgene's Otezla Gains Positive Recommendation from NICE

                                                  by Zacks Equity Research

                                                  Celgene Corporation (CELG) announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination, recommending the use of its oral phosphodiesterase 4, Otezla.